Frontier Medicine
Alzheimer’s-терапія зміщує неврологію до biomarker-gated care
СигналFDA approved Kisunla for adults with Alzheimer’s disease, with treatment initiated in patients with mild cognitive impairment or mild dementia stage, the population studied in clinical trials.
ПатернFrontier medicine is becoming pathway-dependent: value comes from coordinating diagnostics, patient selection, treatment delivery, and monitoring around a narrow biological window.
НаслідокHealth systems need memory clinics, biomarker testing, infusion workflows, MRI monitoring, and payer logic before disease-modifying neurodegeneration therapy can scale responsibly.
ДіяTrack whether diagnostic and monitoring capacity grows fast enough to support biomarker-gated therapies without creating access bottlenecks.